

RESEARCH

Open Access



A cross-tissue transcriptome-wide association study reveals novel susceptibility genes for migraine

Jianxiong Gui^{1†}, Xiaoyue Yang^{1†}, Chen Tan¹, Lingman Wang¹, Linxue Meng¹, Ziyao Han¹, Jie Liu^{1*} and Li Jiang^{1*}

Abstract

Background Migraine is a common neurological disorder with a strong genetic component. Despite the identification of over 100 loci associated with migraine susceptibility through genome-wide association studies (GWAS), the underlying causative genes and biological mechanisms remain predominantly elusive.

Methods The FinnGen R10 dataset, consisting of 333,711 subjects (20,908 cases and 312,803 controls), was utilized in conjunction with the Genotype-Tissue Expression Project (GTEx) v8 EQTLs files to conduct cross-tissue transcriptome association studies (TWAS). Functional Summary-based Imputation (FUSION) was employed to validate these findings in single tissues. Additionally, candidate susceptibility genes were screened using Gene Analysis combined with Multi-marker Analysis of Genomic Annotation (MAGMA). Subsequent Mendelian randomization (MR) and colocalization analyses were conducted. Furthermore, GeneMANIA analysis was employed to enhance our understanding of the functional implications of these susceptibility genes.

Results We identified a total of 19 susceptibility genes associated with migraine in the cross-tissue TWAS analysis. Two novel susceptibility genes, *REV1* and *SREBF2*, were validated through both single tissue TWAS and MAGMA analysis. Mendelian randomization and colocalization analyses further confirmed these findings. *REV1* may reduce the migraine risk by regulating DNA damage repair, while *SREBF2* may increase the risk of migraine by regulating cholesterol metabolism.

Conclusion Our study identified two novel genes whose predicted expression was associated with the risk of migraine, providing new insights into the genetic framework of migraine.

Keywords Migraine, Cross-tissue TWAS, UTMOST, Colocalization, Mendelian randomization

[†]Jianxiong Gui and Xiaoyue Yang have contributed equally to this work and share the first authorship.

*Correspondence:

Jie Liu
JieLiu@hospital.cqmu.edu.cn
Li Jiang
dr_jiangcqmu@163.com

¹Department of Neurology, National Clinical Research Center for Child Health and Disorders, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing Key Laboratory of Child Neurodevelopment and Cognitive Disorders, Children's Hospital of Chongqing Medical University, No. 136, Zhongshan Er Road, Yuzhong District, Chongqing 400014, China



© The Author(s) 2024. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Introduction

Migraine is a prevalent chronic episodic neurological disorder characterized by recurrent attacks, resulting in significant health burden, reduced quality of life, and impaired productivity [1]. It has been recognized as one of the foremost global public health concerns. The Global Burden of Disease Study 2019 (GBD2019) in *Lancet* revealed that migraine ranked second among all human diseases in terms of years lived with disability and was the leading cause of disability-adjusted life years in females aged 15–49 [2], exerting substantial adverse impacts on patients, their families, and society at large. Globally, approximately 1.04 billion individuals suffer from migraine, with a lifetime prevalence estimated at around 8.6% for males and 17% for females [3, 4].

Based on twin and family studies, the heritability of migraine ranges from 35 to 60%, indicating the significant contribution of genetic variation to the susceptibility of migraine [5, 6]. The occurrence of migraine is primarily attributed to a polygenic nature, wherein multiple genetic variants with modest individual effects collectively contribute to the development of the disorder, despite the fact that a single genetic mutation can be sufficient to trigger specific types of migraines such as familial hemiplegic migraine and migraine with aura associated with hereditary small-vessel disorders [7]. In recent years, a genome-wide association study (GWAS) of migraine has identified 123 risk loci associated with the condition [8]. However, many disease trait loci identified by GWAS are situated in non-coding regions, posing challenges in assessing their functional significance [9]. Additionally, complex linkage disequilibrium (LD) can obscure the identification of causal variants driving these associations [10].

Transcriptome-wide association studies (TWAS) integrate expression quantitative trait loci (eQTL) with summary statistics from GWAS to precisely identify candidate genes and investigate gene-trait associations [11]. However, a cross-tissue TWAS methodology known as Unified Test for Molecular Signature (UTMOST) performs gene-level association analyses across multiple tissues [12]. In contrast to single-tissue approaches, this method improves the accuracy and efficacy of imputation models by applying a “group-lasso penalty” that promotes the discovery of shared eQTL effects across different tissues while preserving robust tissue-specific eQTL effects. In recent years, cross-tissue association analysis has been extensively employed in the identification of candidate susceptibility genes for complex multisystem disorders such as rheumatoid arthritis [13], lung cancer [14], and autism spectrum disorder [15]. The present study has unveiled that aside from the prominent role of neurovascular units in migraine [7], there exist interconnections with other tissue units [16, 17].

In this study, we conducted cross-tissue TWAS analysis by integrating migraine GWAS data from the FinnGen R10 with eQTL files from the Genotype-Tissue Expression Project (GTEx) v8. Functional Summary-based Imputation (FUSION) was employed for the assessment of associations in each tissue [18], and Multi-marker Analysis of Genomic Annotation (MAGMA) was performed for validation [19]. Mendelian randomization (MR) and colocalization analysis were carried out on candidate genes, followed by subsequent bioinformatics analyses to explore their biological properties.

Materials and methods

The analysis process is illustrated in Fig. 1.

Migraine GWAS data source

The migraine GWAS data were obtained from the FinnGen R10 dataset (<https://www.finnngen.fi/en>), which consisted of 20,908 cases and 312,803 controls of European ancestry.

eQTL files source

The GTEx V8 dataset [20] encompasses a wealth of gene expression data from 49 different tissues, collected from 838 post-mortem donors (https://ftp.ebi.ac.uk/pub/databases/spot/eQTL/imported/GTEx_V8). The sample sizes varied across different tissues, ranging from 73 samples in the renal cortex to 706 samples in the skeletal muscle.

TWAS analyses in cross-tissue

We employed UTMOST analyses (<https://github.com/Joker-Jerome/UTMOST?tab=readme-ov-file>) in cross-tissue to quantify the overall gene-trait associations at the organismal level. This approach enabled the identification of a greater number of genes within tissues with enriched trait heritability and enhanced imputation accuracy [12, 13]. Subsequently, we employed the generalized Berk-Jones (GBJ) test to integrate gene-trait associations by utilizing covariance from single-tissue statistics [12, 21]. After applying the false discovery rate (FDR) correction, a significance level of $FDR < 0.05$ was considered statistically significant.

TWAS analyses in single tissue

We employed the FUSION tool (<http://gusevlab.org/projects/fusion/>) to conduct TWAS integrating migraine GWAS data with eQTL data from GTEx V8 49 tissues to estimate the association of each gene to disease [22]. Initially, the LD between the prediction model and the SNP at each locus of GWAS was estimated using 1,000 Genomes European samples. Subsequently, FUSION integrates several predictive models (BLUP, BSLMM, LASSO, Elastic Net, and top 1) to evaluate the overall impact of SNPs on gene expression weights. The model




Fig. 1 The flowchart of this study. GWAS, genome-wide association; GTEx, Genotype-Tissues Expression Project; TWAS, transcriptome-wide association studies; UTMOST, unified test for molecular signatures; FUSION, functional summary-based imputation; MAGMA, multi-marker Analysis of GenoMic Annotation

demonstrating the highest predictive performance was then utilized for determining the gene weights [23]. Following this, we combined the genetic effect of migraine (migraine GWAS Z-score) with these gene weights to conduct the TWAS of migraine. The subsequent study included candidate genes that met the following two criteria: (1) $FDR < 0.05$ in cross-tissue TWAS analysis; and (2) $FDR < 0.05$ in at least one tissue in single-tissue TWAS analysis.

Conditional and joint analysis

In FUSION, we may identify multiple associated features within a locus and aim to determine which of these are conditionally independent. Therefore, we conducted conditional and joint (COJO) analysis (the post-process module in FUSION) to identify independent genetic signals [22]. The COJO analysis ensures a more comprehensive understanding of the genetic architecture underlying trait variation by accounting for LD between markers [24]. Following testing, genes that represent independent associations were referred to as jointly significant, while those that no longer showed significance were considered marginally significant.

Gene analysis

For gene analysis, we utilized MAGMA software (version 1.08) with default parameters to aggregate SNP-level association statistics into gene scores, enabling the quantification of each gene's degree of association with the phenotype [25, 26]. For detailed information regarding parameter settings and comprehensive methodological justifications, please refer to the original MAGMA documentation [19].

Mendelian randomization and bayesian colocalization

We conducted MR analysis using the “TwoSampleMR” R package [27]. In this process, we utilized cis-eQTL SNPs as instrumental variables (IVs), gene expression as the exposure, and migraine GWAS as the outcome, respectively. Initially, we selected genome-wide significant SNPs ($p < 5E-08$) and performed LD clumping to obtain independent SNPs ($r^2 < 0.001$) [18]. As only one standalone IV was available, we estimated the MR effect using the Wald ratio with a significance level set at $p < 0.05$.

Subsequently, we conducted a Bayesian colocalization analysis using the “coloc” R package [14, 28] to ascertain whether there is overlap between GWAS and eQTL signals in terms of causal variation loci. This analysis emphasizes the posterior probability (PP) of five relationships [28], with our belief that $PP.H4 > 0.75$, indicating shared causal variants between GWAS and eQTL [14, 29].

GeneMANIA analysis

The GeneMANIA platform [30] (<https://genemania.org/>) integrates diverse genetic interaction, pathway, and co-expression datasets for target genes, along with other gene-function relationships, to enhance comprehension of the underlying biological functions of these targets [31].

Results

TWAS analyses in cross-tissue and single tissue

In the cross-tissue TWAS analysis, a total of 272 genes with $p < 0.05$ were found, (Table S1), out of which 19 genes remained significant even after FDR correction ($FDR < 0.05$) (Table 1). For the validation of the single-tissue TWAS analysis, a total of 144 genes with $FDR < 0.05$ in at least one tissue were identified (Table S2). The statistical outcomes of the 19 genes identified through cross-tissue TWAS analysis are illustrated in Figure S1. A total of 12 candidate genes met strict thresholds in both cross-tissue and single-tissue analyses, comprising 9 coding protein genes (*TEF*, *SREBF2*, *LYG2*, *XRCC6*, *CCDC134*, *SNU13*, *REVI*, *EP300*, and *LYG1*) and 3 non-coding protein genes (*RP5-821D11.7*, *AC109826.1*, and *LINC00634*) (Table S3).

COJO analysis


The 12 candidate genes, primarily located on chromosomes 2 and 22, underwent COJO analysis in their respective tissues to eliminate false positive results arising from LD (Table S4). In *Cells_Cultured_fibroblasts*, conditioning on the predicted expression of *REVI* led to a notable reduction in the TWAS signal for *LYG1* (Figure S2A). In *Colon_Transverse*, the TWAS signal for *LYG2* significantly decreased when conditioned on the predicted expression of *LYG1* (Figure S2B). In *Lung*, conditioning on the predicted expression of *RP5-821D11.7* resulted in a substantial drop in the TWAS signals for *XRCC6* and *CCDC134* (Figure S2C). Moreover, in *Skin_Sun_Exposed_Lower_leg* the TWAS signals for *RP5-821D11.7*, *CCDC134*, and *TEF* markedly diminished when conditioned on the predicted expression of *SREBF2* (Figure S2D). Similarly, in *Whole_Blood*, the TWAS signal for *LYG1* showed a significant decline when the analysis was conditioned on the predicted expression of *REVI* (Figure S2E). Due to *TEF*, *LYG2*, and *XRCC6* achieving significance solely in the TWAS results for an individual tissue and the potential influence of LD on these findings, these genes were not included in further analyses.

Gene analysis of MAGMA

MAGMA gene-based test identified 89 significant genes associated with migraine ($FDR < 0.05$) (Figure S3 and Table S5). To enhance the robustness of our findings, we integrated the UTMOST cross-tissue results with the

Table 1 The significant genes for migraine risk in cross-tissue UTMOST analysis

Gene symbole	CHR	Ensemble ID	Location (hg38)	Test score	p value	FDR
TEF	22	ENSG00000167074	41,367,333–41,399,326	14.76	1.04E-07	3.88E-04
DNPEP	2	ENSG00000123992	219,373,546–219,400,022	13.41	5.82E-07	1.09E-03
MEI1	22	ENSG00000167077	41,699,499–41,799,456	10.94	6.31E-06	5.91E-03
MKL1	22	ENSG00000196588	40,410,290–40,636,702	11.92	5.26E-06	5.91E-03
RP5-821D11.7	22	ENSG00000184068	41,831,215–41,834,665	11.17	9.44E-06	7.06E-03
AC109826.1	2	ENSG00000226791	98,761,938–98,772,920	11.68	1.42E-05	8.83E-03
SREBF2	22	ENSG00000198911	41,866,831–41,907,308	10.72	1.82E-05	8.90E-03
LINC00634	22	ENSG00000205704	41,952,165–41,958,933	10.06	1.90E-05	8.90E-03
SEPT3	22	ENSG00000100167	41,976,272–41,998,221	10.33	3.12E-05	1.17E-02
L3MBTL2	22	ENSG00000100395	41,205,205–41,231,271	9.54	3.13E-05	1.17E-02
LYG2	2	ENSG00000185674	99,242,246–99,255,282	9.31	3.97E-05	1.35E-02
TOB2	22	ENSG00000183864	41,433,492–41,447,023	9.77	5.68E-05	1.64E-02
XRCC6	22	ENSG00000196419	41,621,119–41,664,048	8.94	5.63E-05	1.64E-02
CCDC134	22	ENSG00000100147	41,800,679–41,826,299	8.52	8.86E-05	2.37E-02
LIPT1	2	ENSG00000144182	99,154,965–99,163,157	7.96	1.13E-04	2.82E-02
SNU13	22	ENSG00000100138	41,673,930–41,690,504	8.49	1.68E-04	3.70E-02
REV1	2	ENSG00000135945	99,401,327–99,490,035	8.88	1.66E-04	3.70E-02
EP300	22	ENSG00000100393	41,091,786–41,180,079	7.98	2.06E-04	4.14E-02
LYG1	2	ENSG00000144214	99,284,238–99,304,742	7.05	2.10E-04	4.14E-02

**Fig. 2** Venn diagram. MAGMA identified 89 significant genes associated with hypertension, FUSION identified 144, and UTMOST cross-tissue analysis identified 19, of which 2 were common

significant genes detected by FUSION and MAGMA, resulting in the identification of two promising candidate genes (*REV1* and *SREBF2*) (Fig. 2).

MR and colocalization results

The *REV1* gene is located on chromosome 2q11.2, and FUSION analysis revealed its significant association with

migraine in Whole_Blood and Cells_Cultured_fibroblasts. MR analyses confirmed a causal relationship between *REV1* and migraine ($p < 0.05$). The odds ratios (OR) (95% confidence intervals (CI)) were estimated at 0.74 (0.64, 0.86) for Whole_Blood and 0.86 (0.80, 0.92) for Cells_Cultured_fibroblasts (Fig. 3 and Table S6). Subsequent colocalization analysis further supported this

Gene	Panel	Method	pval	beta	OR (95%CI)
REV1	Whole_Blood	WR	4.77E-05	-0.30	0.74(0.64-0.86)
	Cells_Cultured_fibroblasts	WR	5.27E-05	-0.15	0.86(0.80-0.92)
SREBF2	Testis	WR	3.62E-02	0.09	1.10(1.01-1.19)

Fig. 3 The results of colocalization analysis between candidate genes and migraine. The SNP rs17022564 exhibited the lowest cumulative sum of migraine GWAS and *REV1* eQTL p values both in Whole_Blood (A) and Cells_Cultured_fibroblasts (B). The SNP rs738248 exhibited the lowest cumulative sum of migraine GWAS and *SREBF2* eQTL p values both in Skin_Sun_Exposed_Lower_leg (C) and Testis (D)

finding, with PP.H4 of 0.88 and 0.85 for Whole_Blood and Cells_Cultured_fibroblasts, respectively (Table S7). Notably, rs17022564 emerged as the most significant colocalization locus for migraine in both tissues (Fig. 4A, B).

The *SREBF2* gene is located on chromosome 22q13.2, and the FUSION results demonstrate its significant expression in Skin_Sun_Exposed_Lower_leg and Testis tissues. MR analysis of Testis tissues confirmed a significant causal association with migraine ($p < 0.05$), with an OR (95%CI) of 1.10 (1.01, 1.19). However, no eligible IVs were found in the Skin_Sun_Exposed_Lower_leg tissue (Fig. 3 and Table S6). Furthermore, Colocalization analysis revealed PP.H4 values of 0.73 and 0.87 for these tissues, respectively (Table S7). Among them, rs738248 was identified as the most significant colocalized locus with migraine in both Skin_Sun_Exposed_Lower_leg and Testis tissues (Fig. 4C, D).

GeneMANIA analysis

The potential interaction gene network constructed with *REV1* as the core is shown in Fig. 5A. The most significant functional pathways enriched in *REV1*-related gene networks are postreplication repair, DNA synthesis involved in DNA repair, and translesion synthesis (Table S8). The constructed gene interaction network, with *SREBF2* at its nexus, is depicted in Fig. 5B. The most significant functional pathways enriched in *SREBF2*-related gene networks are sterol biosynthetic process, secondary alcohol biosynthetic process, and cholesterol metabolic process (Table S9).

Discussion

Utilizing migraine GWAS and GTEx V8 eQTL data, we systematically evaluated the relationship between genetic predisposition for gene expression and the risk of migraine. Cross-tissue TWAS analysis, along with validation through single-tissue TWAS and MAGMA, led to the identification of two migraine susceptibility genes (*REV1* and *SREBF2*), which were further substantiated by MR and colocalization analyses. Bioinformatic analyses

enhanced our understanding of the potential functions of these susceptibility genes.

The utilization of multi-omics association studies is currently prevalent in the identification of disease susceptibility genes. The most extensive GWAS meta-analysis of migraine to date has identified 73 potential genes associated with susceptibility to migraine through fine-mapping of causal gene-sets and TWAS analysis [8]. Li et al. identified five genes associated with migraine in human brain tissue and plasma proteomic and transcriptomic analyses, which are mainly expressed in ependymal cells, neurons, and glial cells [23]. Another study utilized imputation models of three TWAS, MASHR, elastic net, and SMultiXcan to identify risk loci for migraine GWAS and potential susceptibility genes [32]. Meyers et al. also employed a TWAS analysis, utilizing eQTL data from GTEx V7, to identify novel candidate susceptibility genes associated with migraine [33]. The variation in outcomes may be attributed to disparities in sample size and source, as well as discrepancies among algorithms employed. However, this emphasizes the significance of conducting multiple avenues of research to identify potential genetic factors contributing to migraine susceptibility. To a certain extent, both of these studies incorporated cross-tissue TWAS analysis [32, 33]; however, it is imperative to further validate the outcomes of the cross-tissue analysis, as their primary focus remained on investigating the association between genes in single tissue and migraine. Moreover, in comparison to GTEx V7, the updated version V8 encompasses a 49% increase in RNA-seq samples derived from 33% more tissue donors, alongside the inclusion of splicing eQTLs [34]. In this study, the cross-tissue TWAS analysis of UTMOST was employed as the core, which improves upon single-tissue TWAS by integrating gene expression data from multiple tissues, increasing statistical power to identify genes associated with complex traits, providing a more comprehensive understanding of gene-trait associations, and enhancing the ability to detect missed associations when analyzing a single tissue in isolation [12]. Currently, the analytical approach of cross-tissue TWAS identification




Fig. 5 GeneMania gene network. (A) *REVI* as the core, and (B) *SREBF2* as the core

association between *REVI* expression and a reduced risk of migraine. Although there was no prior empirical evidence linking *REVI* to migraine, we extrapolated conclusions from its functional characteristics. In *REVI* knockout mice, endogenous DNA damage caused DNA replication stress [38]. Plasma levels of 8-OHdG, a marker for DNA damage, were significantly elevated in migraine patients compared to controls [39]. Moreover, the frequency of headache attacks showed a significant correlation with weather variables, such as the UV index and duration of sunshine [40]. Furthermore, *REVI* has been demonstrated to participate in the DNA damage tolerance induced by UV irradiation in mammals. The expression of *REVI* alone was sufficient to augment the tolerance to UV-induced DNA damage [41]. The inverse correlation between *REVI* expression and migraine risk may be attributed to its regulated role in DNA damage repair, although further studies are required for confirmation.

The *SREBF2* gene encodes a transcription factor that is widely expressed and plays a crucial role in maintaining cholesterol homeostasis by regulating the transcription of sterol-regulated genes. Diseases associated with *SREBF2* include atherosclerosis [42] and adrenoleukodystrophy [43]. The MR analysis revealed a significant association between *SREBF2* expression and the susceptibility to elevated migraine risk. The *SREBF2* gene mutations were identified in patients with autosomal dominant hypercholesterolemia, which may be correlated with elevated levels of cholesterol and glucose [44]. The investigators discovered that elevated levels of lipopolysaccharide (LPS) in patients with cirrhosis resulted in dysregulation of *SREBF2* expression. Increased expression of *SREBF2* induced endoplasmic reticulum stress by

elevating intracellular cholesterol levels and promoting Bax expression, thereby causing additional damage to LPS-induced endothelial cells [45]. Additionally, *SREBF2* facilitated the upregulation of *STARD4* by directly binding to its promoter region, thereby inducing elevated levels of mitochondrial cholesterol, and contributing to the resistance of hepatocellular carcinoma against sorafenib [46]. It has been suggested that migraine frequency and intensity were significantly positively correlated with serum cholesterol levels [47]. In another cross-sectional study, an association was observed between elevated levels of total cholesterol and triglycerides and the occurrence of migraine with aura in older adults [48]. Large-scale plasma metabolomics studies found a consistent association between migraine and decreased high-density lipoprotein (HDL) levels [49]. Considering the significant role of *SREBF2* in regulating cholesterol metabolism and the strong correlation between lipid metabolism and migraine, we postulated that the positive association between *SREBF2* expression and migraine risk may be attributed to its involvement in cholesterol metabolism regulation.

With the large-scale GWAS, numerous reliable SNPs and genes associated with genetic risk factors for migraine have been identified [8, 50]. However, there exist evident challenges in establishing connections between relevant SNPs and genes with potential pathophysiological pathways. Current hypotheses propose that vascular function, metal ion homeostasis, neuronal function, and ion channel activity may be implicated in the pathophysiology of migraine; nevertheless, these notions still necessitate validation through high-throughput experiments conducted on cellular and animal models [51]. We sought to explore the potential interactions

among *SREBF2* or *REV1* and previously identified genes associated with migraine susceptibility [8, 23, 32, 33, 50–53]. However, substantial evidence is currently lacking. Therefore, further investigation is required to elucidate the role of *SREBF2* and *REV1* in migraine pathogenesis.

In summary, the present study identified two novel genes associated with migraine susceptibility, and their potential functions were speculated based on the available results. Our study had several limitations worth noting. Firstly, our sample was exclusively European, limiting the generalizability of our findings across diverse populations. Secondly, despite our multi-faceted approach to reduce the incidence of false positives, the absence of an independent replication dataset posed a limitation to the validation of our results. Lastly, the expression levels of *REV1* and *SREBF2* in tissues previously more closely associated with migraine, such as cerebral arteries, were not able to be assessed and validated in the current dataset. In future studies, a series of biological experiments will be required to corroborate our hypothesized pathophysiological mechanisms. Nevertheless, this study offered novel perspectives and deductions regarding the underlying pathophysiological mechanisms of migraine.

Conclusion

In conclusion, our cross-tissue TWAS analysis identified two novel susceptibility genes whose expression correlated with the risk of migraine, contributing fresh insights into the genetic architecture of this migraine. However, further functional research is necessary to elucidate the potential biological activity of these significant signals.

Supplementary Information

The online version contains supplementary material available at <https://doi.org/10.1186/s10194-024-01802-6>.

Supplementary Material 1

Supplementary Material 2

Acknowledgements

Not applicable.

Author contributions

All authors contributed to the study conception and design. Material preparation, data collection, and analysis were performed by Jianxiong Gui, Xiaoyue Yang, Chen Tan, Lingman Wang, Linxue Meng, and Ziyao Han. The first draft of the manuscript was written by Jianxiong Gui, Xiaoyue Yang, and Jie Liu, and all authors commented on previous versions of the manuscript. The whole process was supervised by Jie Liu and Li Jiang. All authors read and approved the final manuscript.

Funding

The authors declare that no funds, grants, or other support were received during the preparation of this manuscript.

Data availability

The migraine GWAS data were obtained from the FinnGen R10 dataset (https://storage.googleapis.com/finngen-public-data-r10/summary_stats/finngen_R10_G6_MIGRAINE.gz). Gene expression and eQTL data are freely

available at https://ftp.ebi.ac.uk/pub/databases/spot/eQTL/imported/GTEx_V8.

Declarations

Competing interests

The authors declare no competing interests.

Received: 26 April 2024 / Accepted: 31 May 2024

Published online: 05 June 2024

References

- Migraine (2022) *Nat Rev Dis Primers* 8(1:1). <https://doi.org/10.1038/s41572-022-00335-z>
- Steiner TJ, Stovner LJ, Jensen R, Uluduz D, Katsarava Z (2020) Lifting The Burden: the Global Campaign against H. Migraine remains second among the world's causes of disability, and first among young women: findings from GBD2019. *J Headache Pain* 21(1:137). <https://doi.org/10.1186/s10194-020-01208-0>
- Collaborators GBDN (2019) Global, regional, and national burden of neurological disorders, 1990–2016: a systematic analysis for the global burden of Disease Study 2016. *Lancet Neurol* 18 5:459–480. [https://doi.org/10.1016/S1474-4422\(18\)30499-X](https://doi.org/10.1016/S1474-4422(18)30499-X)
- Stovner LJ, Hagen K, Linde M, Steiner TJ (2022) The global prevalence of headache: an update, with analysis of the influences of methodological factors on prevalence estimates. *J Headache Pain* 23(1:34). <https://doi.org/10.1186/s10194-022-01402-2>
- Russell MB, Hilden J, Sørensen SA, Olesen J (1993) Familial occurrence of migraine without aura and migraine with aura. *Neurology* 43 7:1369–1373. <https://doi.org/10.1212/wnl.43.7.1369>
- Russell MB, Olesen J (1995) Increased familial risk and evidence of genetic factor in migraine. *BMJ* 311 7004:541–544. <https://doi.org/10.1136/bmj.311.7004.541>
- Grangeon L, Lange KS, Waliszewska-Prosol M, Onan D, Marschollek K, Wiels W et al (2023) Genetics of migraine: where are we now? *J Headache Pain* 24(1:12). <https://doi.org/10.1186/s10194-023-01547-8>
- Hautakangas H, Winsvold BS, Ruotsalainen SE, Bjornsdottir G, Harder AVE, Kogelman LJA et al (2022) Genome-wide analysis of 102,084 migraine cases identifies 123 risk loci and subtype-specific risk alleles. *Nat Genet* 54(2):152–160. <https://doi.org/10.1038/s41588-021-00990-0>
- Maurano MT, Humbert R, Rynes E, Thurman RE, Haugen E, Wang H et al (2012) Systematic localization of common disease-associated variation in regulatory DNA. *Science* 337 6099:1190–1195. <https://doi.org/10.1126/science.1222794>
- Tam V, Patel N, Turcotte M, Bossé Y, Paré G, Meyre D (2019) Benefits and limitations of genome-wide association studies. *Nat Rev Genet* 20 8:467–484. <https://doi.org/10.1038/s41576-019-0127-1>
- Gamazon ER, Wheeler HE, Shah KP, Mozaffari SV, Aquino-Michaels K, Carroll RJ et al (2015) A gene-based association method for mapping traits using reference transcriptome data. *Nat Genet* 47 9:1091–1098. <https://doi.org/10.1038/ng.3367>
- Hu Y, Li M, Lu Q, Weng H, Wang J, Zekavat SM et al (2019) A statistical framework for cross-tissue transcriptome-wide association analysis. *Nat Genet* 51 3:568–576. <https://doi.org/10.1038/s41588-019-0345-7>
- Ni J, Wang P, Yin KJ, Yang XK, Cen H, Sui C et al (2022) Novel insight into the aetiology of rheumatoid arthritis gained by a cross-tissue transcriptome-wide association study. *RMD Open* 8(2). <https://doi.org/10.1136/rmdopen-2022-002529>
- Zhu M, Fan J, Zhang C, Xu J, Yin R, Zhang E et al (2021) A cross-tissue transcriptome-wide association study identifies novel susceptibility genes for lung cancer in Chinese populations. *Hum Mol Genet* 30 17:1666–1676. <https://doi.org/10.1093/hmg/ddab119>
- Rodriguez-Fontenla C, Carracedo A (2021) UTMOST, a single and cross-tissue TWAS (transcriptome wide association study), reveals new ASD (autism spectrum disorder) associated genes. *Transl Psychiatry* 11(1:256). <https://doi.org/10.1038/s41398-021-01378-8>
- Welander NZ, Rukh G, Rask-Andersen M, Harder AVE, International Headache Genetics C, van den Maagdenberg A et al (2023) Migraine, inflammatory

- bowel disease and celiac disease: a mendelian randomization study. *Headache* 63 5:642–651. <https://doi.org/10.1111/head.14470>
17. Zhang W, Zhang L, Yang L, Xiao C, Wu X, Yan P et al (2023) Migraine, chronic kidney disease and kidney function: observational and genetic analyses. *Hum Genet* 142 8:1185–1200. <https://doi.org/10.1007/s00439-023-02575-9>
 18. Gui J, Meng L, Huang D, Wang L, Yang X, Ding R et al (2024) Identification of novel proteins for sleep apnea by integrating genome-wide association data and human brain proteomes. *Sleep Med* 114:92–99. <https://doi.org/10.1016/j.sleep.2023.12.026>
 19. de Leeuw CA, Mooij JM, Heskes T, Posthuma D (2015) MAGMA: generalized gene-set analysis of GWAS data. *PLoS Comput Biol* 11 4:e1004219. <https://doi.org/10.1371/journal.pcbi.1004219>
 20. The Genotype-Tissue (2013) Expression (GTEx) project. *Nat Genet* 45 6:580–585. <https://doi.org/10.1038/ng.2653>
 21. Sun R, Hui S, Bader GD, Lin X, Kraft P (2019) Powerful gene set analysis in GWAS with the Generalized Berk-Jones statistic. *PLoS Genet* 15(3):e1007530. <https://doi.org/10.1371/journal.pgen.1007530>
 22. Gusev A, Ko A, Shi H, Bhatia G, Chung W, Penninx BW et al (2016) Integrative approaches for large-scale transcriptome-wide association studies. *Nat Genet* 48 3:245–252. <https://doi.org/10.1038/ng.3506>
 23. Li SJ, Shi JJ, Mao CY, Zhang C, Xu YF, Fan Y et al (2023) Identifying causal genes for migraine by integrating the proteome and transcriptome. *J Headache Pain* 24(1:111). <https://doi.org/10.1186/s10194-023-01649-3>
 24. Liao C, Laporte AD, Spiegelman D, Akçimen F, Joobor R, Dion PA et al (2019) Transcriptome-wide association study of attention deficit hyperactivity disorder identifies associated genes and phenotypes. *Nat Commun* 10(1:4450). <https://doi.org/10.1038/s41467-019-12450-9>
 25. de Leeuw CA, Neale BM, Heskes T, Posthuma D (2016) The statistical properties of gene-set analysis. *Nat Rev Genet* 17 6:353–364. <https://doi.org/10.1038/nrg.2016.29>
 26. de Leeuw CA, Stringer S, Dekkers IA, Heskes T, Posthuma D (2018) Conditional and interaction gene-set analysis reveals novel functional pathways for blood pressure. *Nat Commun* 9(1:3768). <https://doi.org/10.1038/s41467-018-06022-6>
 27. Hemani G, Zheng J, Elsworth B, Wade KH, Haberland V, Baird D et al (2018) The MR-Base platform supports systematic causal inference across the human phenotype. *Elife* 7. <https://doi.org/10.7554/eLife.34408>
 28. Giambartolomei C, Vukcevic D, Schadt EE, Franke L, Hingorani AD, Wallace C et al (2014) Bayesian test for colocalisation between pairs of genetic association studies using summary statistics. *PLoS Genet* 10 5:e1004383. <https://doi.org/10.1371/journal.pgen.1004383>
 29. Huang S, Wang J, Liu N, Li P, Wu S, Qi L et al (2023) A cross-tissue transcriptome association study identifies key genes in essential hypertension. *Front Genet* 14:1114174. <https://doi.org/10.3389/fgene.2023.1114174>
 30. Mostafavi S, Ray D, Warde-Farley D, Grouios C, Morris Q (2008) GeneMANIA: a real-time multiple association network integration algorithm for predicting gene function. *Genome Biol* 9(1 Suppl 1):S4. <https://doi.org/10.1186/gb-2008-9-s1-s4>
 31. Warde-Farley D, Donaldson SL, Comes O, Zuberi K, Badrawi R, Chao P et al (2010) The GeneMANIA prediction server: biological network integration for gene prioritization and predicting gene function. *Nucleic Acids Res* 214–220 38 Web Server issue:W. <https://doi.org/10.1093/nar/gkq537>
 32. Ghaffar A, International Headache Genetics C, Nyholt DR (2023) Integrating eQTL and GWAS data characterises established and identifies novel migraine risk loci. *Hum Genet* 142 8:1113–1137. <https://doi.org/10.1007/s00439-023-02568-8>
 33. Meyers TJ, Yin J, Herrera VA, Pressman AR, Hoffmann TJ, Schaefer C et al (2023) Transcriptome-wide association study identifies novel candidate susceptibility genes for migraine. *HGG Adv* 4 3:100211. <https://doi.org/10.1016/j.xhgg.2023.100211>
 34. The GTEx (2020) Consortium atlas of genetic regulatory effects across human tissues. *Science* 369 6509:1318–1330. <https://doi.org/10.1126/science.aaz1776>
 35. Zhu N, Zhao Y, Mi M, Lu Y, Tan Y, Fang X et al (2022) REV1: a novel biomarker and potential therapeutic target for various cancers. *Front Genet* 13:997970. <https://doi.org/10.3389/fgene.2022.997970>
 36. Bi T, Niu X, Qin C, Xiao W (2021) Genetic and physical interactions between Poln and Rev1 in response to UV-induced DNA damage in mammalian cells. *Sci Rep* 11(1:21364). <https://doi.org/10.1038/s41598-021-00878-3>
 37. Kim H, Yang K, Dejsuphong D, D'Andrea AD (2012) Regulation of Rev1 by the fanconi anemia core complex. *Nat Struct Mol Biol* 19(2):164–170. <https://doi.org/10.1038/nsmb.2222>
 38. Panhuis IH, Tsaalbi-Shtylik W, Schonke A, van Harmelen M, Pronk V, Streefland ACM (2022) Rev1 deficiency induces replication stress to cause metabolic dysfunction differently in males and females. *Am J Physiol Endocrinol Metab* 322(3):E319–E29. <https://doi.org/10.1152/ajpendo.00357.2021>
 39. Geyik S, Altunisik E, Neyal AM, Taysi S (2016) Oxidative stress and DNA damage in patients with migraine. *J Headache Pain* 17:10. <https://doi.org/10.1186/s10194-016-0606-0>
 40. Akgun N, Aciman Demirel E, Acikgoz M, Celebi U, Korkturk F, Atasoy HT (2021) The effect of weather variables on the severity, duration, and frequency of headache attacks in the cases of episodic migraine and episodic tension-type headache. *Turk J Med Sci* 51 3:1406–1412. <https://doi.org/10.3906/sag-2004-66>
 41. Niu X, Chen W, Bi T, Lu M, Qin Z, Xiao W (2019) Rev1 plays central roles in mammalian DNA-damage tolerance in response to UV irradiation. *FEBS J* 286 14:2711–2725. <https://doi.org/10.1111/febs.14840>
 42. Rayner KJ, Sheedy FJ, Esau CC, Hussain FN, Temel RE, Parathath S et al (2011) Antagonism of miR-33 in mice promotes reverse cholesterol transport and regression of atherosclerosis. *J Clin Invest* 121 7:2921–2931. <https://doi.org/10.1172/jci57275>
 43. Rampler H, Weinhofer I, Netik A, Forss-Petter S, Brown PJ, Oplinger JA et al (2003) Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy. *Mol Genet Metab* 80 4:398–407. <https://doi.org/10.1016/j.ymgme.2003.09.002>
 44. García-García AB, Martínez-Hervás S, Vernia S, Ivorra C, Pulido I, Martín-Escudero JC et al (2022) A very rare variant in SREBF2, a possible cause of Hypercholesterolemia and increased glyemic levels. *Biomedicines* 10(5). <https://doi.org/10.3390/biomedicines10051178>
 45. Dong G, Huang X, Wu L, Jiang S, Tan Q, Chen S (2022) SREBF2 triggers endoplasmic reticulum stress and Bax dysregulation to promote lipopolysaccharide-induced endothelial cell injury. *Cell Biol Toxicol* 38 1:185–201. <https://doi.org/10.1007/s10565-021-09593-1>
 46. Yue X, Kong Y, Zhang Y, Sun M, Liu S, Wu Z et al (2023) SREBF2-STAR4 axis confers sorafenib resistance in hepatocellular carcinoma by regulating mitochondrial cholesterol homeostasis. *Cancer Sci* 114(2):477–489. <https://doi.org/10.1111/cas.15449>
 47. Tana C, Santilli F, Martelletti P, di Vincenzo A, Cipollone F, Davi G et al (2015) Correlation between migraine severity and cholesterol levels. *Pain Pract* 15 7:662–670. <https://doi.org/10.1111/papr.12229>
 48. Rist PM, Tzourio C, Kurth T (2011) Associations between lipid levels and migraine: cross-sectional analysis in the epidemiology of vascular ageing study. *Cephalalgia* 31 14:1459–1465. <https://doi.org/10.1177/0333102411421682>
 49. Onderwater GLJ, Ligthart L, Bot M, Demirkan A, Fu J, van der Kallen CJH et al (2019) Large-scale plasma metabolome analysis reveals alterations in HDL metabolism in migraine. *Neurology* 92 16:e1899–e911. <https://doi.org/10.1212/WNL.00000000000007313>
 50. Bjornsdottir G, Chalmer MA, Stefansdottir L, Skuladottir AT, Einarsson G, Andresdottir M et al (2023) Rare variants with large effects provide functional insights into the pathology of migraine subtypes, with and without aura. *Nat Genet* 55 11:1843–1853. <https://doi.org/10.1038/s41588-023-01538-0>
 51. van den Maagdenberg A, Nyholt DR, Anttila V (2019) Novel hypotheses emerging from GWAS in migraine? *J Headache Pain* 20 1:5. <https://doi.org/10.1186/s10194-018-0956-x>
 52. Vgontzas A, Renthal W (2020) Migraine-associated gene expression in cell types of the central and peripheral nervous system. *Cephalalgia* 40 5:517–523. <https://doi.org/10.1177/0333102419877834>
 53. Tsao YC, Wang SJ, Hsu CL, Wang YF, Fuh JL, Chen SP et al (2022) Genome-wide association study reveals susceptibility loci for self-reported headache in a large community-based Asian population. *Cephalalgia* 42 3:229–238. <https://doi.org/10.1177/03331024211037269>

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.